News & Events
Published On: 8/24/2020
TARGET-NASH Expands to Europe, Enrolls First Participant
Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its nonalcoholic steatohepatitis (NASH) longitudinal study, TARGET-NASH, has enrolled its first European patient.
“Our TARGET-NASH study continues to grow and lead real-world evidence generation in NASH. TARGET-NASH enrolling its first European patient is an important step forward and will provide important perspectives for our key stakeholders on this growing health concern,” said Target RWE CEO Neal Bibeau.
Launched in 2016, TARGET-NASH is an observational study of more than 5,000 participants diagnosed with nonalcoholic fatty liver disease (NAFLD). Target RWE’s network of sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of this liver disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from TARGET-NASH participants, including Patient-Reported Outcomes (PRO) and biorepository samples.
The TARGET-NASH dataset is critical to providing a baseline and measuring the impact of current practice guidelines, management, and new therapies utilized for patients with medical co-morbidities, hepatic, cardiovascular, and/or other endocrine-associated outcomes.
TARGET-NASH was the first study established by Target RWE when the company was created in 2015. Target RWE has added seven additional studies to its portfolio since then including: hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), asthma, and COVID-19.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
01/04/2024Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions
12/04/2023Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options